# DR. Reddy’s Laboratories Limited (RDY)

- Sector: Healthcare · Industry: Drug Manufacturers Specialty and Generic
- SEC CIK: 0001135951 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001135951))
- Full page: https://inspectstocks.com/stocks/rdy
- Data as of: price 2026-09-25; newest filing used 2026-05-29; latest fiscal period ended 2026-03-31

## Grade

**B+** on the growth-and-cash rubric, 4 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed |  |  |
| Revenue growing recently | passed |  |  |
| Free cash flow positive | passed |  |  |
| Free cash flow growing overall | failed |  |  |
| Free cash flow growing recently | passed |  |  |

Business quality (the + / − mark): 5 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed |  |  |
| Healthy profit margin | passed |  |  |
| Strong operating margin | passed |  |  |
| Good return on equity | failed |  |  |
| Debt under control | passed |  |  |
| Turns sales into cash | passed |  |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, converted from INR at today's spot rate (every period alike).

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $3.5B |
| Net income, trailing twelve months | $446.4M |
| Free cash flow, trailing twelve months | $348.3M |
| Net margin | 12.8% |
| Operating margin | 15.0% |
| Return on equity | 11.4% |
| Debt to equity | 0.21 |
| Diluted EPS, trailing twelve months | $0.71 |
| Share price | $12.25 |
| Market value | $10.2B |
| Price / earnings | 17.3x |
| Price / sales | 2.9x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/rdy)
- [Financial statements](https://inspectstocks.com/stocks/rdy/financials)
- [Competitors](https://inspectstocks.com/stocks/rdy/peers)
- [Earnings](https://inspectstocks.com/stocks/rdy/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.